Satisfaction with and Use of Inhalation Devices in Patients with Bronchial Asthma

Valladales‐Restrepo, Luis Fernando; Saavedra-Navia, Juan Camilo; Montezuma-Casanova, Carlos Andrés; Montañez-Díaz, Valentina; Gonzalez-Ospina, Jairo Andrés; Caballero-Martínez, Laura Manuela; Gaviria‐Mendoza, Andrés; Machado‐Duque, Manuel Enrique; Machado‐Alba, Jorge Enrique

doi:10.1089/jamp.2022.0027

Cited by 3 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 27 In addition, education and training to use the inhalation device is crucial. The vast majority of patients were trained on how to use the inhalation device, consistent with findings in Korea (95.4%) 20 and Colombia (93.9%) 16 and higher than that documented in Spain (80.5%). 28 …”

Section: Discussionsupporting

confidence: 83%

“…A total of 58.9% of COPD patients used metered-dose inhalers, which is in line with previous reports of subjects with asthma in Colombia (73.0%). 16 In Europe and Asia, dry powder inhalers are the predominant devices (61.1–88.9%). 18 , 22 , 25 , 26 According to a systematic review and meta-analysis, COPD patients prefer inhalation devices that are small, durable, easy to use, and quick to administer the drug.…”

Section: Discussionmentioning

confidence: 99%

“… 24 These differences may be due to the academic training of prescribers, the training given to use inhalation devices, the availability of medications and devices, and patient preferences. 16 …”

Section: Discussionmentioning

confidence: 99%

“… 14 An FSI-10 ≥44 points was considered high satisfaction. 15 , 16 Comedications: They were grouped into the following categories: a) antidiabetic drugs (oral and subcutaneous), b) antihypertensive and diuretic drugs, c) lipid-lowering drugs, d) antiulcer drugs, e) antidepressants, f) anxiolytics and hypnotics, g) thyroid hormone, h) antipsychotics, i) antiepileptics, j) antithrombotics, and k) analgesics and anti-inflammatories, among others. …”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Adherence to Inhalation Devices in Patients with Chronic Obstructive Pulmonary Disease

Valladales-Restrepo,

Oyuela-Gutiérrez,

Delgado-Araujo

et al. 2023

PPA

Self Cite

View full text Add to dashboard Cite

Purpose Chronic obstructive pulmonary disease (COPD) affects millions of people around the world. Poor adherence to treatment contributes to increased severity of symptoms, morbidity, and mortality. The objective of this study was to establish the adherence of patients diagnosed with COPD by their devices for inhalation in a group of patients, Colombia. Patients and Methods This was a cross-sectional study of patients treated in the Colombian health system. Adherence to inhalation devices was evaluated with the TAI-10 instrument (Inhaler Adherence Test). A score of 50 points was considered good adherence. Results A total of 500 patients from 84 cities were identified, with a median age of 79.0 years, and 59.2% were women. A total of 45% had GOLD B COPD, and 56.6% had good adherence. Average adherence was 47.4±5.3 points, and no significant differences were found according to inhalation devices (p=0.949). Training performed by specialist physicians (OR: 1.75; 95% CI: 1.17–2.62), use of an inhaler for less than 1 year (OR: 1.59; 95% CI: 1.04–2.43), use of short-acting β2-adrenergic agonists (OR: 1.58; 95% CI: 1.05–2.38) and increased satisfaction with the inhalation device (OR: 1.09; 95% CI: 1.04–1.14) were associated with good adherence, while those from the central region (OR: 0.55; 95% CI: 0.36–0.83), who had a COPD evolution time of less than 5 years (OR: 0.57; 95% CI: 0.37–0.98) and had diabetes mellitus (OR: 0.60; 95% CI: 0.37–0.98) had lower adherence. Conclusion Adherence to treatment with inhaled bronchodilators and glucocorticoids were not very high, with no significant differences by type of inhalation device. Satisfaction and training by specialists increased adherence.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Adherence to Inhalation Devices in Patients with Chronic Obstructive Pulmonary Disease

Valladales-Restrepo,

Oyuela-Gutiérrez,

Delgado-Araujo

et al. 2023

PPA

Self Cite

View full text Add to dashboard Cite

show abstract

“…Since budesonide cannot directly affect leukotriene-mediated processes, as suggested by multiple studies, it has demonstrated inadequate clinical effectiveness in reducing leukotriene-mediated inflammatory reactions. 24,25 Meanwhile, long-term use of budesonide in children easily leads to osteoporosis, decreased adrenocortical function, and other statistically and significantly superior to the control group (P < 0.05). It was concluded that the integration of drugs was conducive to the recovery of immune capacity in children.…”

Section: Comparison Of Symptom Recovery Between Both Groupsmentioning

confidence: 99%

Effect of budesonide combined with montelukast sodium on pulmonary function parameters and immunoglobulin levels in children with bronchial asthma

Chu

Liang

Chen

2023

Allergol Immunopathol

View full text Add to dashboard Cite

Background and aim: Bronchial asthma is a prevalent type of respiratory disease that affects a large proportion of pediatric patients. The purpose of this study is to further investigate the clinical effects of budesonide combined with montelukast sodium in treating bronchial asthma. Methods: Eighty-six children with bronchial asthma were equally divided into study and control groups via randomized double-blind controlled trial. The control group was treated with aerosol inhalation of budesonide combined with placebo, while the study group was treated with budesonide combined with montelukast sodium. Pulmonary function parameters, immunoglobulin, and recovery of related symptoms, along with the adverse reaction rate, were observed and compared between both groups. Results: Before treatment, there was no marked difference in pulmonary function parameters and immunoglobulin indexes between both groups (P > 0.05). All pulmonary function indicators and immunoglobulin indexes in both groups improved following therapy, with the study group outperforming the control group (P < 0.05). The recovery time of related symptoms in the study group was shorter than that in the control group (P < 0.05). The incidence of adverse reactions in both groups was compared, with notable differences (P < 0.05). Conclusion: Budesonide combined with montelukast sodium in the treatment of bronchial asthma has the value of clinical application and promotion.

show abstract

Demographic and Asthma-Related Characteristics of Asthmatics Using Pressurized Metered Dose Inhalers and Dry Powder Inhalers

Aksu,

Vural Solak,

Mutlu

et al. 2024

Journal of Aerosol Medicine and Pulmonary Drug Delivery

View full text Add to dashboard Cite

Satisfaction with and Use of Inhalation Devices in Patients with Bronchial Asthma

Cited by 3 publications

References 29 publications

Adherence to Inhalation Devices in Patients with Chronic Obstructive Pulmonary Disease

Adherence to Inhalation Devices in Patients with Chronic Obstructive Pulmonary Disease

Effect of budesonide combined with montelukast sodium on pulmonary function parameters and immunoglobulin levels in children with bronchial asthma

Demographic and Asthma-Related Characteristics of Asthmatics Using Pressurized Metered Dose Inhalers and Dry Powder Inhalers

Contact Info

Product

Resources

About